291 related articles for article (PubMed ID: 28622036)
1. Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives.
Geng F; Wang Z; Yin H; Yu J; Cao B
Cancer Biother Radiopharm; 2017 Jun; 32(5):149-160. PubMed ID: 28622036
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
Köhne CH; Lenz HJ
Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
[TBL] [Abstract][Full Text] [Related]
3. Options for Second-Line Treatment in Metastatic Colorectal Cancer.
Lee JJ; Sun W
Clin Adv Hematol Oncol; 2016 Jan; 14(1):46-54. PubMed ID: 27057668
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
5. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
Lee JJ; Chu E
Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
[TBL] [Abstract][Full Text] [Related]
6. [Target Therapy in Unresectable or Metastatic Colorectal Cancer].
Kim JH; Park SJ
Korean J Gastroenterol; 2016 Dec; 68(6):303-311. PubMed ID: 28025473
[TBL] [Abstract][Full Text] [Related]
7. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.
Lee YC; Michael M; Zalcberg JR
Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373
[TBL] [Abstract][Full Text] [Related]
8. Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers.
Kasi PM; Hubbard JM; Grothey A
Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):273-6. PubMed ID: 25579664
[TBL] [Abstract][Full Text] [Related]
9. An update on the current and emerging targeted agents in metastatic colorectal cancer.
Chu E
Clin Colorectal Cancer; 2012 Mar; 11(1):1-13. PubMed ID: 21752724
[TBL] [Abstract][Full Text] [Related]
10. Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.
Price TJ; Segelov E; Burge M; Haller DG; Tebbutt NC; Karapetis CS; Punt CJ; Pavlakis N; Arnold D; Gibbs P; Shapiro JD
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1477-93. PubMed ID: 25138900
[TBL] [Abstract][Full Text] [Related]
11. Panitumumab for the treatment of metastatic colorectal cancer: a review.
Del Prete M; Giampieri R; Faloppi L; Bianconi M; Bittoni A; Andrikou K; Cascinu S
Immunotherapy; 2015; 7(7):721-38. PubMed ID: 26250414
[TBL] [Abstract][Full Text] [Related]
12. Current controversies in the management of metastatic colorectal cancer.
Vera R; Alonso V; Gállego J; González E; Guillén-Ponce C; Pericay C; Rivera F; Safont MJ; Valladares-Ayerbes M
Cancer Chemother Pharmacol; 2015 Oct; 76(4):659-77. PubMed ID: 26113053
[TBL] [Abstract][Full Text] [Related]
13. Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer.
Jain VK; Hawkes EA; Cunningham D
Clin Colorectal Cancer; 2011 Dec; 10(4):245-57. PubMed ID: 21729675
[TBL] [Abstract][Full Text] [Related]
14. Emerging VEGF-receptor inhibitors for colorectal cancer.
Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
[TBL] [Abstract][Full Text] [Related]
15. Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials.
Advani S; Kopetz S
J Surg Oncol; 2019 Apr; 119(5):642-652. PubMed ID: 30852840
[TBL] [Abstract][Full Text] [Related]
16. Anti-metastatic treatment in colorectal cancer: targeting signaling pathways.
Lemos C; Sack U; Schmid F; Juneja M; Stein U
Curr Pharm Des; 2013; 19(5):841-63. PubMed ID: 22973955
[TBL] [Abstract][Full Text] [Related]
17. A paradigm shift from one-size-fits-all to tailor-made therapy for metastatic colorectal cancer.
Weinberg BA; Marshall JL; Hartley M; Salem ME
Clin Adv Hematol Oncol; 2016 Feb; 14(2):116-28. PubMed ID: 27057810
[TBL] [Abstract][Full Text] [Related]
18. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
[TBL] [Abstract][Full Text] [Related]
19. Critical evaluation of current treatments in metastatic colorectal cancer.
Venook A
Oncologist; 2005 Apr; 10(4):250-61. PubMed ID: 15821245
[TBL] [Abstract][Full Text] [Related]
20. Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.
Caiazza F; Elliott L; Fennelly D; Sheahan K; Doherty GA; Ryan EJ
Biomark Med; 2015; 9(4):363-75. PubMed ID: 25808440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]